Results delivered in prestigious Proffered Paper oral presentation at ESMO Congress 2024In patients with any PD-L1 expression (CPS ≥1), efti in combination with KEYTRUDA outperformance is largest in CPS ≥20 with 31.0% ORR (34.5% ORR including partial response after data cut-off) versus 18.5% ORR for KEYTRUDAEfti in combination with KEYTRUDA led to a high durability of response of 17.5 months in patients with any PD-L1 expression and combination continues to have favourable safety profileStatistically signif ...

Immutep Limited Preliminary final report Exhibit 99.1 APPENDIX 4E PRELIMINARY FINAL REPORT 1. Company details | --- | --- | |------------------------------------|---------------------------------| | | | | | | | Name of entity: | Immutep Limited | | ABN: | 90 009 237 889 | | Reporting period: | Year ended 30 June 2024 | | Previous corresponding period: | Year ended 30 June 2023 | 2. Results for announcement to the market | --- | --- | --- | --- | --- | |------------------------------------------------------- ...

Media Release Entered into third and most important clinical trial collaboration and supply agreement to date with MSD to evaluate eftilagimod alfa (efti) in combination with KEYTRUDA® (pembrolizumab) and chemotherapy for first-line non-small cell lung cancer in a pivotal Phase III trialContinuing positive clinical data reported from efti: Positive results from TACTI-003 Phase IIb trial in first-line head and neck squamous cell carcinoma with efti in combination with KEYTRUDA®Encouraging efficacy and safety ...

Immutep Limited (IMMP) jumped 14.9% after it announced positive results from cohort B of the late-stage TACTI-003 (KEYNOTE-PNC-34) study. The study evaluated the combination of its pipeline candidate eftilagimod alfa (efti) and Merck's (MRK) Keytruda (pembrolizumab) as a first-line treatment for patients with recurrent or metastatic head and neck squamous cell carcinoma (1L HNSCC) with negative PD-L1 expression.Efti is Immutep’s proprietary soluble LAG-3 protein and MHC Class II agonist, which is being deve ...

文章核心观点 - 免疫治疗组合efti和KEYTRUDA在1L HNSCC患者(CPS<1)中取得35.5%的客观缓解率,这是目前无化疗治疗方案中最高的结果之一 [3] - 该组合治疗还取得9.7%的完全缓解率,远高于单用抗PD-1单药的历史对照 [4] - 该组合治疗的疗效持续性良好,超过50%的患者接受治疗至少6个月 [6] - 该组合治疗的安全性良好,未观察到新的安全信号 [6] 公司和行业相关内容 - 该免疫治疗组合利用efti激活抗原递呈细胞,增强了免疫检查点抑制剂KEYTRUDA的疗效 [7] - efti是目前唯一一种处于临床开发阶段的MHC Class II激动剂,可以在不同PD-L1表达水平的患者中产生广泛的抗肿瘤免疫反应 [7] - 基于良好的疗效和高未满足医疗需求,公司将与监管机构讨论后续发展计划 [8][9] - efti已获得FDA在1L HNSCC适应症的快速通道资格,这一适应症中CPS<1、CPS 1-19和CPS>20的患者分别占约20%、30%和50% [9]

Media Release Efti in combination with KEYTRUDA® (pembrolizumab) achieved a 35.5% response rate in evaluable patients (N=31), according to RECIST 1.1, among the highest recorded for a treatment approach not containing chemotherapy in patients with CPS <1High complete response rate of 9.7% with three patients showing a disappearance of cancer lesions post treatmentDurability of responses tracks well and over 50% of patients received treatment for at least six monthsCombination continues to have a favourable ...

文章核心观点 - Prima BioMed Ltd (IMMP)股价最近遭受过度抛售压力,已经跌入超卖区域 [1][5] - 华尔街分析师预计公司将报告优于此前预期的盈利 [1] - 根据相对强弱指数(RSI)的测算,IMMP股价已经处于超卖状态,有望出现反弹 [2][3][4][5] - 分析师对IMMP当前年度的盈利预测也有所上调,这通常会带来股价的近期上涨 [6][7] 行业和公司分析 - IMMP目前的Zacks排名为2(买入),位于4000多只股票中前20%,这进一步表明其有望在短期内实现反弹 [7] - 尽管RSI是一个有用的技术指标,但不应单独依赖它做出投资决策 [4]

Media Release SYDNEY, AUSTRALIA, June 25, 2024 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a clinical-stage biotechnology company developing novel LAG-3 immunotherapies for cancer and autoimmune diseases, today announces a License Agreement with Cardiff University granting the Company exclusive rights to develop and commercialise anti-LAG-3 small molecules. A number of promising compounds that block LAG-3, an immune checkpoint known to reduce the immune system’ ...

Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 ((ASX: IMM, NASDAQ:IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). The Placement and Instit ...

Sydney, Australia, June 05, 2024 (GLOBE NEWSWIRE) -- Immutep Limited ACN 009 237 889 ((ASX: IMM, NASDAQ:IMMP) (Immutep or the Company) is pleased to announce the successful completion of its institutional placement (Placement) and the institutional component (Institutional Entitlement Offer) of its 1 for 16 pro rata accelerated non-renounceable entitlement offer (Entitlement Offer and, together with the Placement, the Offer) of new fully paid ordinary shares in Immutep (New Shares). The Placement and Instit ...